Cargando…
HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
Constitutively stabilized HSP90 client proteins are crucial for cancer cell survival and proliferation. Thus, despite—or perhaps because of—their pleiotropic effects on variety of critical oncoproteins, HSP90 inhibitors represent a promising new class of anticancer drugs. We identified MIF as an ess...
Autores principales: | Schulz, Ramona, Dobbelstein, Matthias, Moll, Ute M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518525/ https://www.ncbi.nlm.nih.gov/pubmed/23243616 http://dx.doi.org/10.4161/onci.21173 |
Ejemplares similares
-
MIF: metastasis/MDSC-inducing factor?
por: Simpson, Kendra D., et al.
Publicado: (2013) -
Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade
por: Liu, Jiao, et al.
Publicado: (2022) -
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
por: Schulz, Ramona, et al.
Publicado: (2012) -
HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
por: Schulz, R, et al.
Publicado: (2014) -
Recruitment of γδ T lymphocytes to tumors: A new role for the pleiotropic chemokine CCL2
por: Lança, Telma, et al.
Publicado: (2013)